A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5‐drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5‐drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study
复制标题
间歇性化疗与连续化疗以及阿霉素与甲氨蝶呤 5 种药物化疗治疗晚期乳腺癌 A 癌症和白血病 B 组研究的比较
DOI：
--
复制
发表时间：
1984
期刊：
影响因子：
--
通讯作者：
J. Holland
中科院分区：
文献类型：
--
作者：
D. Tormey;V. Weinberg;L. Leone;O. Glidewell;M. Perloff;B. Kennedy;E. Cortes;R. Silver;R. Weiss;J. Aisner;J. Holland
在转移性乳腺癌患者中，评价了间歇性与连续性联合化疗以及在5种药物方案中用阿霉素替代甲氨蝶呤的治疗效果。患者被随机分配接受环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、长春新碱、泼尼松（CMFVP-C，86例患者）、间歇性CMFVP（CMFVP-I，109例患者）或间歇性CAFVP（107例患者）的连续治疗。CAFVP的CR + PR率（71%）上级CMFVP-C（50%，p = 0.003）和CMFVP-I（50%，p = 0.002）。CAFVP的缓解持续时间（14个月，中位数）上级CMFVP-I（7个月）（p < 0.01），并倾向于上级CMFVP-C（9个月）（p = 0.07）。CAFVP的生存优势（19个月，中位数）优于CMFVP-I（13个月）（p = 0.01），但不优于CMFVP-C（16个月）（p = 0.24）。在CR + PR患者中，CAFVP的生存期（29个月，中位数）上级CMFVP-I（18个月）和CMFVP-C（21个月）（p = 0. 02）。CMFVP-C方案的白细胞减少症和神经系统毒性发生率最高，但胃肠道毒性发生率最低。结果表明，CAFVP方案耐受性良好，上级CMFVP方案。
THE THERAPEUTIC EFFECTIVENESS OF INTERMITTENT vs. continuous combination chemotherapy and of the substitution of adriamycin for methotrexate in a 5-drug regimen was evaluated in women with metastatic breast carcinoma. Patients were randomly allocated to receive continuous therapy with cyclophosphamide, methotrexate, 5-fluo-rouracil, vincristine, prednisone (CMFVP-C, 86 patients), intermittent CMFVP (CMFVP-I, 109 patients), or intermittent CAFVP (107 patients). The CR + PR rate with CAFVP (71%) was superior to CMFVP-C (50%, p = 0.003) and to CMFVP-I (50%, p = 0.002). The remission duration with CAFVP (14 months, median) was superior to CMFVP-I (7 months) (p < 0.01), and tended to be superior to CMFVP-C (9 months) (p = 0.07). There was a survival advantage of CAFVP (19 months, median) over CMFVP-I (13 months) (p = 0.01), but not over CMFVP-C (16 months) (p = 0.24). Among CR + PR patients, the survival with CAFVP (29 months, median) was superior (p = 0.02) to both CMFVP-I (18 months) and CMFVP-C (21 months). The CMFVP-C regimen was associated with the highest incidence of leukopenia and neurologic toxicity, but the lowest incidence of GI toxicity. The results indicate that the CAFVP regimen is well tolerated and is superior to the CMFVP regimens.